Gilead Sciences Inc. (GILD)

74.40
1.14 1.56
NASDAQ : Health Technology
Prev Close 73.26
Open 74.38
Day Low/High 73.36 / 74.55
52 Wk Low/High 60.89 / 85.97
Volume 12.51M
Avg Volume 22.29M
Exchange NASDAQ
Shares Outstanding 1.25B
Market Cap 94.25B
EPS 4.20
P/E Ratio 19.27
Div & Yield 2.72 (3.30%)
Biotech Should Witness M&A's Return in 2017

Biotech Should Witness M&A's Return in 2017

Drug giants with money to spend and a friendlier regulatory environment should spur deals.

My Takeaways and Observations

"Who you tryin' to get crazy with, 'ese? Don't you know I'm loco?..." -- Cypress Hill, Insane in the Brain 2017 will be the year of "The Dude."    My favorite large-cap long Allergan  and short Caterpillar   for next year.  AGN closed up by $4(!) wh...

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

My Takeaways and Observations (2:45 p.m. EST edition)

"First gear, it's all right (Honda, Honda, go faster, faster) Second gear, I'll lean right (Honda, Honda, go faster, faster) Third gear, hang on tight (Honda, Honda, go faster, faster) Faster, it's all right." -- Beach Boys, "Little Honda"  With a b...

Expect Some Big-Cap Biotech Love in 2017

We touched briefly on housing in our first post this morning. There are still some cheap home-building stocks if the housing market continues to improve, which I expect as I believe economic growth will pick up in 2017. I have done well with this se...

2 Biotech Giants Poised for a Better 2017

2 Biotech Giants Poised for a Better 2017

Here's why Gilead and Celgene should finally reward their shareholders next year.

My Takeaways and Observations

"Everyone here likes the bounce." -- President-elect Donald Trump (said in a meeting today at Trump Tower with tech executives) A good day for the ursine crowd but not so good for the bullish cabal as they had a bad day -- for a change. (Yes, I am w...

Cramer: Rate-Hike Silver Linings Playbook Gets Dusted Off

Cramer: Rate-Hike Silver Linings Playbook Gets Dusted Off

There's a reason why FANG is back -- though it never really went away.

Gilead's Decline Appears to Be Ending

Gilead's Decline Appears to Be Ending

The long downtrend is looking mature.

My Takeaways and Observations

Was yesterday "FOMO" or something else?    I waited and then moved on the volatility trade.    "How many syllables Mario?" (A Putney Swope reference!)    Wall Street is now a fear-free zone.    Mark Hanson on negative homeowners' equity.    Shorted ...

This May Be 2016's Top Stock-Selection Model

This May Be 2016's Top Stock-Selection Model

The 'Enterprise Value Growth and Income' stock-picking model should be quite effective in 2017, too.

I'm Buying Biotech on This Trump Scare

I'm Buying Biotech on This Trump Scare

If the market is going to overreact to every new missive from Trump, I plan to take advantage.

Hold Your Breath When Diving for Deep Value

Hold Your Breath When Diving for Deep Value

It can take many months or quarters before the market recognizes the value of a downtrodden name.

My Takeaways and Observations

"Well, they call you lady luck But there is room for doubt At times you have a very un-lady-like way Of running out..." -- Guys and Dolls, Luck Be A Lady (Frank Sinatra)  Trump will not likely Make Twitter Great Again.   I, bear.    Explaining my pr...

My Takeaways and Observations

What a strange day -- maybe even ominous.   This table tells it all.    The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...

'Yuge' Sector Rotation Will Continue

'Yuge' Sector Rotation Will Continue

What's in, what's out and who should thrive in the new political landscape.

Looking for Shorts (In All the Right Places)

In looking for shorts there is one important and underlying factor that governs my selection process: I try through rigorous analysis to identify sectors and companies with intermediate-term prospects that are deteriorating relative to consensus exp...

Piper Healthcare Conf.

My Takeaways and Observations (3:30 p.m. Edition)

It may be time to embrace the contrary.    First issue (!!): The Palm Beach Chronicles.   My weekly (brief) technical review of the markets -- cooling off ahead?    BTIG's Stockton is bullish and so, as I have expressed, are most others!   Campbell ...

Some 'January Effect' Stock Picks

Some 'January Effect' Stock Picks

Small-caps could also benefit from abating tax-loss selling.

Some Black Friday Stock Market Buys

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Biotech Stocks May be Cheap But Large Scale M&A May Elude the Sector

Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.

The Good, the Bad and the Ugly (3 p.m. Edition)

It's not a joke. It's a rope, Tuco. Now I want you to get up there and put your head in that noose. -- Blondie in "The Good, the Bad and the Ugly" I did no trading today, and there will be no "Takeaways" today. As expected, the markets have basicall...

2 Small-Cap Biotech Buyout Targets

2 Small-Cap Biotech Buyout Targets

With the election resolved, biotech could be ripe for consolidation.

Don't Count on a Rally for Gilead

Don't Count on a Rally for Gilead

I would look for GILD to try to stabilize in the $70-$80 area before a more durable uptrend.

My Takeaways and Observations

At the end of the day!    Don't run with the crowd: Embrace contrary and second-level thinking instead.    Extreme policy uncertainty.    More Howard Marks.    Less Bill Miller.    My little sister!    Graf wrote a goodie.    The movie was in revers...

Credit Suisse Healthcare Conf.

Some Potential Positives Today

Some potential positives today: Strength in the Russell Index. Improving breadth. Improving Clinton odds by "538" and the London betting parlors. A great deal of pushback to my idea of a trading rally. Turnaround in large-cap biotech (Allergan , Cel...

What Makes for a Truly Great Stock?

What Makes for a Truly Great Stock?

This century's best-performing names offer some clues.